Clinical trials: Peritoneal (metastatic) Cancer
Stage IV Gastric Cancer With Metastasis
Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer
A maximum of 8 cycles of chemotherapy will be administered. Depending on patients' tolerability, 8 cycles of chemotherapy will be given to the patients.
- Trial name
- XPID (NCT01525771)
- Testing
- Docetaxel
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer, Advanced Colorectal Cancer
SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases
The goal of this clinical trial is to see if high- and low-dose radiotherapy combined with immunotherapy can work in patients with advanced gastric, colorectal, and ovarian cancers with peritoneal metastases, and to learn about…
- Conditions
- Advanced Gastric Cancer, Advanced Colorectal Cancer, Advanced Ovarian Cancer, Peritoneal Metastasis
- Trial name
- NCT06940921
- Testing
- Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Zhang Tao
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
This early phase I trial tests the safety and side effects of ZN-c3 in treating patients with triple-negative breast cancer or ovarian cancer that have spread to other parts of the body (metastatic or advanced).
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT05368506
- Testing
- Wee1 Inhibitor ZN-c3
- Sponsor
- OHSU Knight Cancer Institute
Ovarian Cancer
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
This is a multicenter, open-label study of safety and efficacy of Quisinostat in combination with Paclitaxel + Carboplatin chemotherapy in patients with metastatic or locally advanced epithelial ovarian cancer, primarily…
- Trial name
- NCT02948075
- Testing
- Quisinostat, Paclitaxel, Carboplatin
- Where
- 6 sites in Russia
- Volunteers
- 31 people
- Sponsor
- NewVac LLC
Ovarian Cancer, Fallopian Tube
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination.
- Conditions
- Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
- Trial name
- NCT02737787
- Testing
- WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer, Gynecologic Cancer
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy (RT) to at least one metastatic lesion during routine care.
- Conditions
- Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer
- Trial name
- OLIGYNE-10 RT (NCT07883798)
- Testing
- Routine-care metastasis-directed radiotherapy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
For peritoneal metastatic gastric/gastroesophageal junction adenocarcinoma (cT3-4NanyM1), PD-1 antibody combined with chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) can downstage tumor stage, increase the…
- Conditions
- Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis
- Trial name
- NCT06914687
- Testing
- Tislelizumab, S-1, Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Peritoneal Tumor
MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors
This study is a single-arm, dose-escalation, investigator-initiated exploratory clinical trial designed to evaluate the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of MT027 Cell Injection in patients…
- Trial name
- NCT07004647
- Testing
- Fludarabine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Gastric Cancer Peritoneal Metastases
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.
- Trial name
- NCT06487715
- Testing
- albumin-bound paclitaxel (260 mg/m2, d1), S-1, sintilimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
The goal of this phase II randomized controlled clinical trial is to evaluate whether adding lubiprostone to standard postoperative maintenance therapy can delay disease progression and recurrence in adult patients with…
- Conditions
- Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer, Peritoneal Metastasis, Colorectal Cancer (CRC)
- Trial name
- NCT07405736
- Testing
- maintenance therapy plus lubiprostone, maintenance therapy
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer Stage IV, Peritoneal Metastases
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.
- Trial name
- NCT06519591
- Testing
- Cadonilimab, LM-302, S-1, paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Peritoneal Neoplasms, Neoplasm Metastasis
HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry
In this registry study the investigators will collect data about patients' disease, treatment, and response to treatment to include in both our local and national databases.
- Conditions
- Peritoneal Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma
- Trial name
- NCT02082886
- Where
- 2 sites in United States
- Volunteers
- 193 people
- Sponsor
- Edward-Elmhurst Health System